Limits...
Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy.

Lin M, Mao Y, Ai S, Liu G, Zhang J, Yan J, Yang H, Li A, Zou Y, Liang D - Int J Endocrinol (2015)

Bottom Line: Methods.Conclusions.SD doxycycline appears to be effective and safe for the treatment of active and moderate-to-severe GO.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, No. 54 Xianlie Road, Guangzhou 510060, China.

ABSTRACT
Aim. To study the efficacy and safety of subantimicrobial dose (SD) doxycycline(50 mg/d) in patients with active and moderate-to-severe Graves' orbitopathy (GO). Methods. Thirteen patients with active and moderate-to-severe GO received once daily oral doxycycline (50 mg/d) for 12 wk. Treatment response at 24 wk was used as the primary outcome, measured by a composite of improvement in Clinical Activity Score (CAS), diplopia, motility, soft tissue swelling, proptosis, and eyelid aperture. Secondary outcome was the change of quality of life score (QoL, including visual functioning subscale and appearance subscale). Adverse events were also recorded. Results. Overall improvement was noted in eight out of 13 patients (61.5%, 95% CI 31.6%-86.1%). Both CAS and soft tissue swelling significantly ameliorated in eight patients at 24 wk. Five patients (38.5%) had improvement in ocular motility of ≥8 degrees. Eyelid aperture (46.2%) also decreased remarkably. For QoL, a significant improvement in appearance subscale (P = 0.008) was noted during the study, whereas no difference was observed in visual functioning subscale (P = 0.21). Two patients reported mild stomachache at 12 wk. Conclusions. SD doxycycline appears to be effective and safe for the treatment of active and moderate-to-severe GO. It might serve as a new promising therapeutic strategy for GO. This trial is registered with NCT01727973.

No MeSH data available.


Related in: MedlinePlus

Representative example of patients status at baseline and at 24 wk after the start of treatment. (a) (baseline) and (b) (24 wk) showed that soft tissue involvements and redness of conjunctiva were remarkably improved in a female at 24 wk. (c) (baseline) and (d) (24 wk) showed the improvement of eyelid aperture, lid lag, and elevation in a male treated by doxycycline.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499606&req=5

fig1: Representative example of patients status at baseline and at 24 wk after the start of treatment. (a) (baseline) and (b) (24 wk) showed that soft tissue involvements and redness of conjunctiva were remarkably improved in a female at 24 wk. (c) (baseline) and (d) (24 wk) showed the improvement of eyelid aperture, lid lag, and elevation in a male treated by doxycycline.

Mentions: The mean scores on the GO-QoL questionnaire at baseline and after the intervention were also shown in Table 2. A significant improvement in appearance subscale (P = 0.008) was found during the study, whereas no difference was noted in visual functioning subscale (P = 0.21). The typical changes of appearance were demonstrated in Figure 1.


Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy.

Lin M, Mao Y, Ai S, Liu G, Zhang J, Yan J, Yang H, Li A, Zou Y, Liang D - Int J Endocrinol (2015)

Representative example of patients status at baseline and at 24 wk after the start of treatment. (a) (baseline) and (b) (24 wk) showed that soft tissue involvements and redness of conjunctiva were remarkably improved in a female at 24 wk. (c) (baseline) and (d) (24 wk) showed the improvement of eyelid aperture, lid lag, and elevation in a male treated by doxycycline.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499606&req=5

fig1: Representative example of patients status at baseline and at 24 wk after the start of treatment. (a) (baseline) and (b) (24 wk) showed that soft tissue involvements and redness of conjunctiva were remarkably improved in a female at 24 wk. (c) (baseline) and (d) (24 wk) showed the improvement of eyelid aperture, lid lag, and elevation in a male treated by doxycycline.
Mentions: The mean scores on the GO-QoL questionnaire at baseline and after the intervention were also shown in Table 2. A significant improvement in appearance subscale (P = 0.008) was found during the study, whereas no difference was noted in visual functioning subscale (P = 0.21). The typical changes of appearance were demonstrated in Figure 1.

Bottom Line: Methods.Conclusions.SD doxycycline appears to be effective and safe for the treatment of active and moderate-to-severe GO.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, No. 54 Xianlie Road, Guangzhou 510060, China.

ABSTRACT
Aim. To study the efficacy and safety of subantimicrobial dose (SD) doxycycline(50 mg/d) in patients with active and moderate-to-severe Graves' orbitopathy (GO). Methods. Thirteen patients with active and moderate-to-severe GO received once daily oral doxycycline (50 mg/d) for 12 wk. Treatment response at 24 wk was used as the primary outcome, measured by a composite of improvement in Clinical Activity Score (CAS), diplopia, motility, soft tissue swelling, proptosis, and eyelid aperture. Secondary outcome was the change of quality of life score (QoL, including visual functioning subscale and appearance subscale). Adverse events were also recorded. Results. Overall improvement was noted in eight out of 13 patients (61.5%, 95% CI 31.6%-86.1%). Both CAS and soft tissue swelling significantly ameliorated in eight patients at 24 wk. Five patients (38.5%) had improvement in ocular motility of ≥8 degrees. Eyelid aperture (46.2%) also decreased remarkably. For QoL, a significant improvement in appearance subscale (P = 0.008) was noted during the study, whereas no difference was observed in visual functioning subscale (P = 0.21). Two patients reported mild stomachache at 12 wk. Conclusions. SD doxycycline appears to be effective and safe for the treatment of active and moderate-to-severe GO. It might serve as a new promising therapeutic strategy for GO. This trial is registered with NCT01727973.

No MeSH data available.


Related in: MedlinePlus